Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clint T Allen

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
JCI Insight|April 5, 2019
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapyLillian Sun, Paul E Clavijo, Yvette Robbins, et al.
Frontiers in Oncology|May 14, 2024
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrenceDiana C Lopez, Kellsye P Fabian, Michelle R Padget, et al.
Oncoimmunology|November 1, 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesKristin C Hicks, Massimo Fantini, Renee N Donahue, et al.
Elife|July 8, 2020
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cellsYvette Robbins, Sarah Greene, Jay Friedman, et al.
Iscience|September 23, 2024
Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse modelsDaniel E Tsai, Alexei Lovanov, Abdalla Abdelmaksoud, et al.
Journal of Translational Medicine|September 11, 2024
Correction to: Augmentation of tumor expression of HLADR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responsesRiley M Larkin, Diana C Lopez, Yvette L Robbins, et al.
Journal of Translational Medicine|May 31, 2024
Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responsesRiley M Larkin, Diana C Lopez, Yvette L Robbins, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 5, 2024
Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer modelsLucas A Horn, Hanne Lind, Kristen Fousek, et al.
NPJ Precision Oncology|April 18, 2026
GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapyCem M Sievers, Tian-Gen Chang, Yvette Robbins, et al.
Nature Communications|June 13, 2026
Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancerCem Sievers, Yvette Robbins, Marco Craveiro, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
JCI Insight|April 5, 2019
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapyLillian Sun, Paul E Clavijo, Yvette Robbins, et al.
Frontiers in Oncology|May 14, 2024
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrenceDiana C Lopez, Kellsye P Fabian, Michelle R Padget, et al.
Oncoimmunology|November 1, 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesKristin C Hicks, Massimo Fantini, Renee N Donahue, et al.
Elife|July 8, 2020
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cellsYvette Robbins, Sarah Greene, Jay Friedman, et al.
Iscience|September 23, 2024
Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse modelsDaniel E Tsai, Alexei Lovanov, Abdalla Abdelmaksoud, et al.
Journal of Translational Medicine|September 11, 2024
Correction to: Augmentation of tumor expression of HLADR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responsesRiley M Larkin, Diana C Lopez, Yvette L Robbins, et al.
Journal of Translational Medicine|May 31, 2024
Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responsesRiley M Larkin, Diana C Lopez, Yvette L Robbins, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 5, 2024
Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer modelsLucas A Horn, Hanne Lind, Kristen Fousek, et al.
NPJ Precision Oncology|April 18, 2026
GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapyCem M Sievers, Tian-Gen Chang, Yvette Robbins, et al.
Nature Communications|June 13, 2026
Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancerCem Sievers, Yvette Robbins, Marco Craveiro, et al.
Pageof 11